Literature DB >> 15523707

Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.

Ming Tan1, Hong-Bin Fang, Guo-Liang Tian, Peter J Houghton.   

Abstract

In cancer drug development, xenograft experiments (models) where mice are grafted with human cancer cells are used to elucidate the mechanism of action and/or to assess efficacy of a promising compound. Demonstrated activity in this model is an important step to bring a promising compound to humans. A key outcome variable in these experiments is tumour volumes measured over a period of time, while mice are treated with an anticancer agent following certain schedules. However, a mouse may die during the experiment or may be sacrificed when its tumour volume quadruples and then incomplete repeated measurements arise. The incompleteness or missingness is also caused by drastic tumour shrinkage (<0.01 cm3) or random truncation. In addition, if no treatment were given to the tumour-bearing mice, the tumours would keep growing until the mice die or are sacrificed. This intrinsic growth of tumour in the absence of treatment constrains the parameters in the regression and causes further difficulties in statistical analysis. We develop a maximum likelihood method based on the expectation/conditional maximization (ECM) algorithm to estimate the dose-response relationship while accounting for the informative censoring and the constraints of model parameters. A real xenograft study on a new anti-tumour agent temozolomide combined with irinotecan is analysed using the proposed method. 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15523707     DOI: 10.1002/sim.1775

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor Sizes.

Authors:  Philippe B Pierrillas; Michel Tod; Magali Amiel; Marylore Chenel; Emilie Henin
Journal:  AAPS J       Date:  2016-06-21       Impact factor: 4.009

2.  Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments.

Authors:  Lili Zhao; Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence; Daniel Normolle
Journal:  Clin Cancer Res       Date:  2010-12-03       Impact factor: 12.531

3.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

4.  Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.

Authors:  Xiu-Fen Liu; Laiman Xiang; David J FitzGerald; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2013-10-21       Impact factor: 6.261

5.  Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.

Authors:  Kingshuk Roy Choudhury; Stephen T Keir; Kathleen A Ashcraft; Mary-Keara Boss; Mark W Dewhirst
Journal:  Oncotarget       Date:  2015-06-10

6.  Patient-derived xenograft (PDX) tumors increase growth rate with time.

Authors:  Alexander T Pearson; Kelsey A Finkel; Kristy A Warner; Felipe Nör; David Tice; Manoela D Martins; Trachette L Jackson; Jacques E Nör
Journal:  Oncotarget       Date:  2016-02-16

7.  Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals.

Authors:  Emma C Martin; Leon Aarons; James W T Yates
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-25       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.